86 related articles for article (PubMed ID: 12447867)
1. Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study.
King JK; Yeh SH; Lin MW; Liu CJ; Lai MY; Kao JH; Chen DS; Chen PJ
Hepatology; 2002 Dec; 36(6):1416-24. PubMed ID: 12447867
[TBL] [Abstract][Full Text] [Related]
2. [Genetic polymorphisms of MxA protein and eIF-2a-reg2 and their responses to interferon treatment in patients with chronic hepatitis B].
Huang YX; Ma LN; Chen XY; Li Z; Huang YL; Shen CL; Ma B
Zhonghua Gan Zang Bing Za Zhi; 2007 Mar; 15(3):187-91. PubMed ID: 17407708
[TBL] [Abstract][Full Text] [Related]
3. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
[TBL] [Abstract][Full Text] [Related]
4. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection.
Suzuki F; Arase Y; Suzuki Y; Tsubota A; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Takagi K; Satoh J; Kumada H
J Viral Hepat; 2004 May; 11(3):271-6. PubMed ID: 15117331
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in the interferon-gamma gene at position +874 in patients with chronic hepatitis C treated with high-dose interferon-alpha and ribavirin.
Dai CY; Chuang WL; Chang WY; Chen SC; Lee LP; Hsieh MY; Hou NJ; Lin ZY; Hsieh MY; Wang LY; Yu ML
Antiviral Res; 2005 Aug; 67(2):93-7. PubMed ID: 16051377
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial.
Karabay O; Tamer A; Tahtaci M; Vardi S; Celebi H
J Microbiol Immunol Infect; 2005 Aug; 38(4):262-6. PubMed ID: 16118673
[TBL] [Abstract][Full Text] [Related]
7. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C.
Tsukada H; Ochi H; Maekawa T; Abe H; Fujimoto Y; Tsuge M; Takahashi H; Kumada H; Kamatani N; Nakamura Y; Chayama K
Gastroenterology; 2009 May; 136(5):1796-805.e6. PubMed ID: 19208361
[TBL] [Abstract][Full Text] [Related]
8. Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection.
Wietzke-Braun P; Maouzi AB; Mänhardt LB; Bickeböller H; Ramadori G; Mihm S
Eur J Gastroenterol Hepatol; 2006 Sep; 18(9):991-7. PubMed ID: 16894313
[TBL] [Abstract][Full Text] [Related]
9. Lack of interferon sensitivity-determining region in the genome of hepatitis B virus genotype Ba.
Liu CJ; Chen PJ; Lai MY; Chen TC; Wang HY; Huang WL; Kao JH; Chen DS
Antivir Ther; 2004 Dec; 9(6):895-903. PubMed ID: 15651748
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.
van Zonneveld M; Honkoop P; Hansen BE; Niesters HG; Darwish Murad S; de Man RA; Schalm SW; Janssen HL
Hepatology; 2004 Mar; 39(3):804-10. PubMed ID: 14999700
[TBL] [Abstract][Full Text] [Related]
11. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
[TBL] [Abstract][Full Text] [Related]
12. The haplotype of the MxA gene promoter is associated with hepatitis B virus infection in a Chinese population.
Cao B; Liu X; Hou F; Li W; Han Z; Zhang Q; Dai Y; Xu C; Qi H
Liver Int; 2009 Oct; 29(9):1383-8. PubMed ID: 19744071
[TBL] [Abstract][Full Text] [Related]
13. Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients.
Wada M; Marusawa H; Yamada R; Nasu A; Osaki Y; Kudo M; Nabeshima M; Fukuda Y; Chiba T; Matsuda F
J Viral Hepat; 2009 Jun; 16(6):388-96. PubMed ID: 19200137
[TBL] [Abstract][Full Text] [Related]
14. Response to antiviral treatment in patients infected with hepatitis B virus genotypes E-H.
Erhardt A; Göbel T; Ludwig A; Lau GK; Marcellin P; van Bömmel F; Heinzel-Pleines U; Adams O; Häussinger D
J Med Virol; 2009 Oct; 81(10):1716-20. PubMed ID: 19697400
[TBL] [Abstract][Full Text] [Related]
15. Autoantibodies in children with chronic hepatitis B infection and the influence of interferon alpha.
Kansu A; Kuloğlu Z; Demirçeken F; Girgin N
Turk J Gastroenterol; 2004 Dec; 15(4):213-8. PubMed ID: 16249973
[TBL] [Abstract][Full Text] [Related]
16. Intrahepatic CD8 T-lymphocytes and HBV core expression in relation to response to antiviral therapy for chronic hepatitis B patients.
Tang TJ; de Man RA; Kusters JG; Kwekkeboom J; Hop WC; van der Molen RG; Schalm SW; Janssen HL
J Med Virol; 2004 Feb; 72(2):215-22. PubMed ID: 14695662
[TBL] [Abstract][Full Text] [Related]
17. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphism of interferon-gamma, interferon-gamma receptor, and interferon regulatory factor-1 genes in patients with hepatitis B virus infection.
Cheong JY; Cho SW; Chung SG; Lee JA; Yeo M; Wang HJ; Lee JE; Hahm KB; Kim JH
Biochem Genet; 2006 Jun; 44(5-6):246-55. PubMed ID: 16944293
[TBL] [Abstract][Full Text] [Related]
19. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.
Saito T; Ito T; Ishiko H; Yonaha M; Morikawa K; Miyokawa A; Mitamura K
Am J Gastroenterol; 2003 Jun; 98(6):1377-83. PubMed ID: 12818284
[TBL] [Abstract][Full Text] [Related]
20. STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma.
Ito N; Eto M; Nakamura E; Takahashi A; Tsukamoto T; Toma H; Nakazawa H; Hirao Y; Uemura H; Kagawa S; Kanayama H; Nose Y; Kinukawa N; Nakamura T; Jinnai N; Seki T; Takamatsu M; Masui Y; Naito S; Ogawa O
J Clin Oncol; 2007 Jul; 25(19):2785-91. PubMed ID: 17602083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
